// App-Quantinova.ai

: Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI at two ICS dose levels in the ETHOS trial: a subgroup analysis

Researchers

Presenter

  • Klaus F. Rabe

Principal Investigators

  • Fernando J. Martinez

  • Gary T. Ferguson

  • Chen Wang

  • Dave Singh

  • Jadwiga A. Wedzicha

  • Roopa Trivedi

  • Earl St Rose

  • Shaila Ballal

  • Julie Mclaren

  • Patrick Darken

  • Magnus Aurivillius

  • Colin Reisner

  • Paul Dorinsky

Medical Centers

  • LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany,

  • Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States,

  • Pulmonary Research Institute of Southeast Michigan, Farmingtin Hills, MI, United States.

  • National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.

  • Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom,

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • AstraZeneca, Gaithersberg, MD, United States,

  • AstraZeneca, Gothenburg, Sweden

Locations

  • Germany

  • United States

  • China

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • budesonide + formoterol fuma

  • Seebri Breezhaler

  • Budesonide

  • Formoterol

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02465567

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved